Dataset Information

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.

ABSTRACT: Some patients with acute myeloid leukemia (AML) who are in complete remission after induction chemotherapy harbor persisting pre-leukemic clones, carrying a subset of leukemia-associated somatic mutations. There is conflicting evidence on the prognostic relevance of these clones for AML relapse. Here, we characterized paired pre-treatment and remission samples from 126 AML patients for mutations in 68 leukemia-associated genes. Fifty patients (40%) retained ?1 mutation during remission at a VAF of ?2%. Mutation persistence was most frequent in DNMT3A (65% of patients with mutations at diagnosis), SRSF2 (64%), TET2 (55%), and ASXL1 (46%), and significantly associated with older age (p?

SUBMITTER: Rothenberg-Thurley M

PROVIDER: S-EPMC6035153 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.

Rothenberg-Thurley Maja M Amler Susanne S Goerlich Dennis D Köhnke Thomas T Konstandin Nikola P NP Schneider Stephanie S Sauerland Maria C MC Herold Tobias T Hubmann Max M Ksienzyk Bianka B Zellmeier Evelyn E Bohlander Stefan K SK Subklewe Marion M Faldum Andreas A Hiddemann Wolfgang W Braess Jan J Spiekermann Karsten K Metzeler Klaus H KH

Leukemia 20180223 7

Some patients with acute myeloid leukemia (AML) who are in complete remission after induction chemotherapy harbor persisting pre-leukemic clones, carrying a subset of leukemia-associated somatic mutations. There is conflicting evidence on the prognostic relevance of these clones for AML relapse. Here, we characterized paired pre-treatment and remission samples from 126 AML patients for mutations in 68 leukemia-associated genes. Fifty patients (40%) retained ≥1 mutation during remission at a VAF ...[more]

PMID: 29472724

Dataset Information

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.

Publications

Persistence of pre-leukemic clones during first remission and risk of relapse in acute myeloid leukemia.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets

Similar Datasets

Remission maintenance in acute myeloid leukemia: impact of functional histamine H2 receptors expressed by leukemic cells.
| S-EPMC3590096 | biostudies-literature

Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia.
| S-EPMC6008108 | biostudies-literature

Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial.
| S-EPMC4450623 | biostudies-literature

Single-cell analysis reveals altered tumor microenvironments of relapse- and remission-associated pediatric acute myeloid leukemia.
| S-EPMC10556066 | biostudies-literature

Isolated Intracranial Myeloid Sarcoma Occurring as Relapse in Acute Myeloid Leukemia.
| S-EPMC5488578 | biostudies-other

Persistent <i>IDH1/2</i> mutations in remission can predict relapse in patients with acute myeloid leukemia.
| S-EPMC6355476 | biostudies-literature

Monitoring dendritic cell and cytokine biomarkers during remission prior to relapse in patients with FLT3-ITD acute myeloid leukemia.
| S-EPMC3701796 | biostudies-other

Relapse after Prolonged Remission in Philadelphia-Like Acute Lymphoblastic Leukemia.
| S-EPMC6360594 | biostudies-literature

Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia.
| S-EPMC7054545 | biostudies-literature

Isolated leukemia cutis as extramedullary relapse of acute myeloid leukemia.
| S-EPMC9354096 | biostudies-literature